cytarabine has been researched along with cladribine in 144 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (15.97) | 18.2507 |
| 2000's | 42 (29.17) | 29.6817 |
| 2010's | 53 (36.81) | 24.3611 |
| 2020's | 26 (18.06) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, R; Nelson, JA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Björck, L; Clausen, AR; Piskur, J; Sandrini, MP; Shannon, O | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
| Csoka, K; Larsson, R; Liliemark, J; Nygren, P | 1 |
| Fridborg, H; Killander, A; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P; Oberg, G; Simonsson, B | 1 |
| Evans, SS; Messenger, JC; Nagourney, RA; Su, YZ; Weisenthal, LM | 1 |
| Hansz, J; Kozłowska-Skrzypczak, M; Sawiński, K | 1 |
| Chucrallah, A; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Estey, EH; Kantarjian, HM; Keating, MA | 1 |
| Hapke, DM; Mitchell, BS; Stegmann, AP | 1 |
| Andreeff, HM; Beran, M; Estey, E; Gandhi, V; Kantarjian, HM; Koller, CA; Kornblau, SM; O'Brien, S; Plunkett, W | 1 |
| Wiley, JS | 1 |
| Baldwin, SA; Beaumont, N; Boumah, CE; Cass, CE; Coe, I; Davies, A; Griffiths, M; Kwong, FY; Sundaram, M; Yao, SY; Young, JD | 1 |
| Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K | 1 |
| Cohen, JD; Katz, TB; Marcel, PD; Strock, DJ; Teik, JE | 1 |
| Brismar, S; Johansson, M; Karlsson, A | 1 |
| Cory, AH; Cory, JG; Nelson, TO; Somerville, L | 1 |
| Albertioni, F; Eriksson, S; Hullán, L; Sasvári-Székely, M; Spasokoukotskaja, T; Staub, M | 1 |
| Johansson, M; Karlsson, A; Permert, J; Zhu, C | 1 |
| Guchelaar, HJ; Haanen, C; Koopmans, RP; Reutelingsperger, CP; Vermes, I | 1 |
| Geisen, F; Konwalinka, G; Schirmer, M; Stegmann, AP | 1 |
| Aleskog, A; Höglund, M; Kristensen, J; Larsson, R; Sundström, C | 1 |
| Callet Bauchu, E; Dumontet, C; Fabianowska-Majewska, K; Fang, X; Gandhi, V; Gazzo, S; Lepoivre, M; MacKey, J; Mantincic, D; Peters, GJ; Rolland, MO; Tigaud, I; Vanier-Viornery, A; Voorn, DA; Wyczechowska, D | 1 |
| Albertioni, F; Larsson, BS; Liliemark, J; Lindemalm, S | 1 |
| Allegra, CJ; Chabner, BA; Chu, E; Grem, JL; Johnston, PG; Multani, P; Ryan, D; Takimoto, CH | 1 |
| Lorsbach, RB; Mathew, S; Raimondi, SC; Sandlund, JT; Shearer, P | 1 |
| Dmoszyńska, A; Kowal, M; Lech-Marańda, E; Robak, T; Wrzesień-Kuś, A | 1 |
| Johansson, M; Karlsson, A; Zheng, X | 1 |
| Albertioni, F; Chandra, J; Eriksson, S; Knaust, E; Liliemark, E; Lotfi, K; Månsson, E; Spasokoukotskaja, T; Wang, Y; Xu, D | 1 |
| Behm, FG; Pritchard, M; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Srivastava, DK; Tong, X | 1 |
| Johnson, SA | 1 |
| Akabutu, JJ; Gati, WP; Grundy, PE; Paterson, AR; Sowa, B; Wright, AM | 1 |
| Baker, KS; Nagarajan, R; Neglia, J; Ramsay, N | 1 |
| Ault, P; Cortes, J; Kaled, ES; Kantarjian, H; Koller, C | 1 |
| Behm, FG; Crews, KR; Gandhi, V; Plunkett, W; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Srivastava, DK; Stewart, CF; Tong, X | 1 |
| Creutzig, U; Hählen, K; Harbott, J; Huismans, DR; Kaspers, GJ; Pieters, R; Slater, RM; Veerman, AJ; Zimmermann, M; Zwaan, CM | 1 |
| Crews, KR; Howard, SC; Hudson, JQ; Razzouk, BI; Ribeiro, RC; Wimmer, PS | 1 |
| Baldwin, SA; Cass, CE; Clarke, ML; Mackey, JR; Young, JD | 1 |
| Robak, T | 1 |
| Bangaru, BS; Choi, SW; Finlay, JL; Wu, CD | 1 |
| Dmoszyńska, A; Grosicki, S; Hellmann, A; Hołowiecki, J; Jedrzejczak, W; Kowal, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Lech-Marańda, E; Maj, S; Robak, T; Skotnicki, A; Wierzbowska, A; Wrzesień-Kuś, A | 1 |
| Barete, S; Bonté, I; Casassus, P; de Gennes, C; Fain, O; Hermine, O; Lortholary, O; Marrache, F; Mémain, N | 1 |
| Björkholm, M; Höglund, M; Juliusson, G; Karlsson, K; Löfgren, C; Möllgård, L; Paul, C; Tidefelt, U | 1 |
| Baran, W; Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jagoda, K; Jakubas, B; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Konopka, L; Kuliczkowski, K; Kyrcz-Krzemien, S; Marianska, B; Paluszewska, M; Pluta, A; Robak, T; Skotnicki, A; Stella-Holowiecka, B; Sulek, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
| Elinder, G; Kimby, E; Sverrisdottir, A | 1 |
| Pui, CH; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Santana, VM; Srivastava, DK | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Hennessy, B; Kantarjian, H; O'brien, S; Ossa, G; Verstovsek, S | 1 |
| Aleskog, A; Höglund, M; Larsson, R; Laurell, A; Lindhagen, E; Nilsson, K; Nygren, P; Roos, G; Rosenquist, R; Sundström, C; Thunberg, U; Tobin, G | 1 |
| Broekhuizen, AJ; Hubeek, I; Kaspers, GJ; Peters, GJ | 1 |
| Badowska, W; Balcerska, A; Balwierz, W; Czyzewski, K; Debski, R; Juraszewska, E; Konatkowska, B; Kowalczyk, J; Krawczuk-Rybak, M; Kuzmicz, M; Malinowska, I; Matysiak, M; Olejnik, I; Ploszynska, A; Sońta-Jakimczyk, D; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanski, T; Wachowiak, J; Wieczorek, M; Wysocki, M | 1 |
| Dumontet, C; Galmarini, CM; Jordheim, LP | 1 |
| Baran, W; Dmoszyńska, A; Grosicki, S; Hellmann, A; Hołowiecki, J; Kiebiński, M; Krawczyńska, A; Kuliczkowski, K; Kyrcz-Krzemień, S; Lech-Marańda, E; Mazur, G; Pluta, A; Robak, T; Wach, M; Wawrzyniak, E; Wierzbowska, A; Wrzesień-Kuś, A | 1 |
| Andreeff, M; Cortes, J; Gandhi, V; Garcia-Manero, G; Giles, F; Jabbour, E; Jackson, CE; Kantarjian, H; O'Brien, S; Plunkett, W; Verstovsek, S | 1 |
| Agarwal, RP; Chou, TC; Fernandez, M; Han, T | 1 |
| Albertioni, F; Löfgren, C; Paul, C | 1 |
| McClain, KL | 1 |
| Bernard, F; Bertrand, Y; Chastagner, P; Colin, VM; Donadieu, J; Landman Parker, J; Munzer, M; Ouache, M; Perel, Y; Thomas, C; Vermylen, C | 1 |
| Gratwohl, A; Rimner, T; Tichelli, A; Went, P | 1 |
| Bergman, AM; Eijk, PP; Peters, GJ; Smid, K; van den Ijssel, P; van Haperen, VW; Veerman, G; Ylstra, B | 1 |
| Gojkovic, Z; Hasholt, L; Joergensen, T; Knecht, W; Le Breton, C; Munch-Petersen, B; Piskur, J; Rozpedowska, E; Sandrini, MP; Willer, M | 1 |
| Cebula, B; Giebel, S; Grosicki, S; Hołowiecki, J; Kiełbiński, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Kłoczko, J; Piatkowska-Jakubas, B; Pluta, A; Robak, T; Skotnicki, AB; Wawrzyniak, E; Wierzbowska, A; Wrzesień-Kuś, A; Zawilska, K | 1 |
| Abboud, C; Becker, M; Friedberg, J; Ifthikharuddin, J; Komrokji, RS; Liesveld, JL; Messina, P; Mulford, D; Oliva, J; Phillips, G; Walker, AR | 1 |
| Apollonsky, N; Lipton, JM | 1 |
| Campana, D; Crews, KR; Downing, JR; Gandhi, VV; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Yang, S | 1 |
| Dutka, M; Flont, M; Gawronski, K; Giebel, S; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Konopka, L; Kuliczkowski, K; Lech-Maranda, E; Paluszewska, M; Palynyczko, G; Piatkowska-Jakubas, B; Robak, T; Seweryn, M; Skotnicki, A; Sokolowski, J; Sulek, K; Szpila, T; Warzocha, K; Wegrzyn, J; Zdziarska, B | 1 |
| Alla, CA; Arbion, F; Blouin, P; Colombat, P; Donadieu, J; Eitenschenck, L; Emile, JF; Machet, MC; Pagnier, A; Plantaz, D; Yvert, M | 1 |
| Teh, TC; Wei, A | 1 |
| Fernandez, HF; George, TJ; Ho, VQ; Kharfan-Dabaja, MA; Komrokji, RS; Lancet, JE; List, AF; Pinilla-Ibarz, J; Price, SL; Wetzstein, GA | 1 |
| Fukuda, Y; Schuetz, JD | 1 |
| Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L | 1 |
| Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Robak, T; Skotnicki, AB; Sulek, K; Wach, M; Warzocha, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
| Bowman, WP; Campana, D; Cao, X; Dahl, G; Inaba, H; Jenkins, L; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Taub, JW | 1 |
| Campana, D; Cao, X; Crews, KR; Dolan, ME; Downing, J; Gandhi, V; Hartford, C; Lamba, JK; Mitra, AK; Plunkett, W; Pounds, S; Raimondi, S; Ribeiro, RC; Rubnitz, JE | 1 |
| Abdulrezzak, U; Cetin, M; Kaynar, L; Keklik, M; Kontas, O; Sivgin, S | 1 |
| Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Robak, T; Wierzbowska, A | 1 |
| Abboud, CN; Cashen, A; Dipersio, JF; Fiala, M; McBride, A; Ramsingh, G; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P | 1 |
| Hernandez, F; Jaksa, R; Klanova, M; Klener, P; Kulvait, V; Lateckova, L; Lorkova, L; Maswabi, B; Mavis, C; Molinsky, J; Petrak, J; Pospisilova, J; Trneny, M; Vejmelkova, D; Vit, O; Vockova, P; Vokurka, M | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Brennig, S; Czarnecki, K; Dilloo, D; Heinz, N; Heise, M; Heuser, M; Kaever, V; Kempf, H; Lachmann, N; Moritz, T; Phaltane, R; Schambach, A | 1 |
| Amaral, D; Braier, JL; Chantada, G; Latella, A; Rosso, DA | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, M; Fleischhack, G; Graf, N; Gruhn, B; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Stray, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M | 1 |
| Arico, M; Armari Alla, C; Bardet, O; Barkaoui, M; Bernard, F; Clausen, N; Donadieu, J; Gandemer, V; Henter, JI; Jeziorski, E; Lambilliote, A; Mura, R; Piguet, C; Van Den Bos, C; van Noesel, M; Weitzman, S | 1 |
| Stine, KC | 1 |
| Chen, J; Liu, Y; Shen, Y; Wu, D | 1 |
| Jamy, O; Martin, MG; Wiedower, E | 1 |
| Borg, K; Calbecka, M; Czekalska, S; Ejduk, A; Florek, I; Gadomska, G; Gajkowska-Kulik, J; Giebel, S; Grosicki, S; Haus, O; Holowiecki, J; Jakobczyk, M; Jazwiec, B; Jedrzejczak, WW; Karabin, K; Kata, D; Kielbinski, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Libura, J; Libura, M; Matiakowska, K; Paluszewska, M; Pawelczyk, M; Piatkowska-Jakubas, B; Skotnicki, A; Solarska, I; Warzocha, K; Wierzbowska, A; Zawada, M | 1 |
| Goto, H; Goto, S; Yokosuka, T | 1 |
| Chao, Z; Chen, XM; Deng, CX; DU, X; Huang, X; Lai, PL; Li, MM; Liao, PJ; Ling, W; Lu, ZS; Wan, CC; Wang, YL; Weng, JY; Wu, SJ; Zhong, LY; Zou, XL | 1 |
| Ahmed, N; Baskind, P; Liu, D; Seiter, K; Shaikh, A | 1 |
| Bieber, T; Irnich, M; Maintz, L; Reinhard, H; Wenzel, J | 1 |
| Duan, MH; Feng, J; Han, X; Li, J; Tian, LP; Yang, C; Zhang, L; Zhang, M; Zhang, W; Zhang, Y; Zhou, DB | 1 |
| Bang, SM; Kim, I; Koh, Y; Lee, JO; Park, H; Park, S; Yoon, SS; Youk, J | 1 |
| Fridle, C; Manz, MG; Medinger, M; Pabst, T; Passweg, J; Seipel, K; Wilk, MC | 1 |
| Bakane, A; Balaji, R; Raj, R; Ramachandrakurup, S; Subburaj, D; Uppuluri, R | 1 |
| Butrym, A; Czemerska, M; Giebel, S; Golos, A; Grosicki, S; Holowiecka-Goral, A; Holowiecki, J; Katarzyna Budziszewska, B; Kloczko, J; Kuliczkowski, K; Kyrcz-Krzemien, S; Lange, A; Madry, K; Mordak-Domagala, M; Piszcz, J; Pluta, A; Razny, M; Robak, T; Sulek, K; Szydlo, R; Warzocha, K; Wawrzyniak, E; Wierzbowska, A; Wiktor-Jedrzejczak, W; Wrzesien-Kus, A; Zwolinska, M | 1 |
| Braun, JT; Freter, CE; Lionberger, JM; Petruska, PJ; Ramlal, R; Schoen, MW; Woelich, SK | 1 |
| Imai, C; Imamura, M; Iwabuchi, H; Kawashima, H; Ogose, A; Saitoh, A; Takachi, T; Umezu, H | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Ali, AM; Cooley, SA; DiPersio, JF; Miller, JS; Rashidi, A; Romee, R; Shanley, R; Ustun, C; Vij, KR; Weisdorf, DJ; Westervelt, P | 1 |
| Cubitt, C; Komrokji, RS; Lancet, JE; List, AF; Mirza, AS; Nardelli, L; Padron, E; Pinilla-Ibarz, J; Sweet, K | 1 |
| Evans, AG; Goorha, S; Hobbs, ALV; Leonard, JM; Mills, EL; Seligson, ND | 1 |
| Andreeff, M; Benton, CB; Boddu, P; Borthakur, G; Cortes, J; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Patel, K; Ravandi, F; Takahashi, K | 1 |
| Messina, J; Nethers, K; Seminario-Vidal, L | 1 |
| Braun, JT; Fesler, MJ; Freter, CE; Lionberger, JM; Petruska, PJ; Reddy, DV; Schoen, MW; Woelich, SK | 1 |
| Brayer, J; Rose, A | 1 |
| Huang, Y; Liu, DD; Lv, TT; Xu, J; Yuan, GL; Zhou, XF | 1 |
| Abughanimeh, O; Bahaj, W; Foxworth, J; Gaur, R; Qasrawi, A; Qasrawi, L | 1 |
| Andritsos, LA; Grever, MR; Kaffenberger, BH; Kuehn, GJ; Wang, RF | 1 |
| Lv, T; Tian, X; Wang, L; Xu, J; Yuan, G | 1 |
| Kontopoulou, E; Kunz, F; Reinhardt, D; Reinhardt, K; Soldierer, M; Strachan, S; Thakur, BK | 1 |
| Hu, Y; Huang, H; Jin, A; Jin, M; Luo, Y; Tan, Y; Wei, G; Wu, W; Yang, L; Yu, J | 1 |
| Bodzenta, E; Bolkun, L; Brzozowski, K; Czemerska, M; Giebel, S; Gromek, T; Grosicki, S; Grzybowska-Izydorczyk, O; Helbig, G; Hellman, A; Holowiecki, J; Hus, M; Kloczko, J; Knopinska-Posluszny, W; Krawczynska, A; Kuydowicz, M; Lech-Maranda, E; Nowicki, M; Patkowska, E; Piekarska, A; Pluta, A; Razny, M; Robak, T; Sobas, M; Stelmach, P; Stepka, K; Szmigielska-Kaplon, A; Warzocha, K; Wawrzyniak, E; Wierzbowska, A; Wojcik, K; Wrobel, T | 1 |
| Chen, K; Jiang, H; Li, H; Shao, JB; Yang, JW; Zhang, N; Zhu, JS | 1 |
| Breccia, M; Capria, S; Foa, R; Jabbour, E; Kadia, TM; Molica, M; Trisolini, S | 1 |
| Abboud, CN; Abboud, R; Chendamarai, E; DiPersio, JF; Ghobadi, A; Pusic, I; Rettig, MP; Riedell, PA; Schroeder, MA; Stockerl-Goldstein, K; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
| Kong, P; Yao, H | 1 |
| Brossart, P; Glasmacher, A; Hahn-Ast, C; Mayer, K; Schmidt-Wolf, IGH; Schwab, K; von Lilienfeld-Toal, M | 1 |
| Becker, PS; Buckley, SA; Estey, EH; Halpern, AB; Hendrie, PC; Oehler, VG; Othus, M; Palmieri, R; Percival, MM; Scott, BL; Walter, RB | 1 |
| Basak, GW; Drozd-Sokolowska, J; Dwilewicz-Trojaczek, J; Gierej, B; Halaburda, K; Karakulska-Prystupiuk, E; Sachs, W; Tormanowska, M; Urbanowska, E; Wiktor-Jedrzejczak, W | 1 |
| Becker, PS; Godwin, CD; Halpern, AB; Othus, M; Palmieri, R; Percival, MM; Walter, RB | 1 |
| Gulati, N | 1 |
| Chen, XJ; Chen, YM; Guo, Y; Liu, F; Liu, LP; Liu, TF; Liu, XM; Quan Qi, B; Ruan, M; Yang, WY; Zhang, AL; Zhang, L; Zhu, XF; Zou, Y | 1 |
| Baron, J; Cronin, TL; Elshoury, A; Freyer, CW; Griffiths, EA; Ji, W; Muppidi, MR; Ontiveros, EP; Przespolewski, A; Thompson, JE; Thota, S; Wang, ES | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Pemmaraju, N; Pierce, S; Popat, U; Rausch, C; Ravandi, F; Verstovsek, S; Wang, X | 1 |
| Gao, W; Hu, J; Jiang, J; Wan, M; Wang, L | 1 |
| DU, Y; Li, H; Li, JX; Lu, WJ; Qi, SS; Tao, F; Xiong, H; Yang, L; Zhang, LN | 1 |
| Andreeff, M; Bhalla, KN; Borthakur, G; Daver, NG; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, HM; Konopleva, MY; Malla, R; Montalban-Bravo, G; Ohanian, M; Pemmaraju, N; Popat, UR; Quagliato, K; Rausch, CR; Ravandi, F; Reville, PK; Sasaki, K; Short, NJ; Takahashi, K; Wang, X | 1 |
| Alsdorf, WH; Bokemeyer, C; Brauneck, F; Fiedler, W; Ghandili, S; Karagiannis, P; Klingler, F; Modemann, F; Wolschke, C | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
| Bazinet, A; Borthakur, G; Chien, KS; Darbaniyan, F; Daver, NG; DiNardo, CD; Garcia-Manero, G; Hammond, D; Jabbour, EJ; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, HM; Konopleva, MY; Montalban-Bravo, G; Pemmaraju, N; Pierce, SA; Ravandi, F; Sasaki, K; Venugopal, S | 1 |
| Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H | 1 |
| Appelbaum, J; Curley, N; Estey, EH; Gooley, T; Halpern, AB; Hendrie, PC; Kopmar, NE; Lim, J; Percival, MM; Russell, K; Schonhoff, K; Scott, BL; Shaw, C; Walter, RB | 1 |
| Baidildina, D; Bronin, G; Burtsev, E; Cherniak, E; Dzhukaeva, I; Erega, E; Evseev, D; Fink, O; Ignatova, A; Kalinina, I; Kotskaya, N; Litvin, E; Lyudovskikh, E; Maschan, A; Maschan, M; Novichkova, G; Osipova, D; Popov, A; Pristanskova, E; Purbueva, B; Raykina, E; Semchenkova, A; Vlasova, I; Voronin, K; Zhogov, V | 1 |
| Abkowitz, JL; Appelbaum, JS; Becker, PS; Cassaday, RD; Estey, EH; Garcia, KA; Ghiuzeli, MC; Halpern, AB; Hendrie, PC; Keel, SB; Oehler, VG; Orozco, JJ; Othus, M; Percival, MM; Rodríguez-Arbolí, E; Scott, BL; Walter, RB | 1 |
| Bataller, A; Borthakur, G; Bose, P; Champlin, R; Daver, N; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Islam, R; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Marx, KR; Molica, M; Pemmaraju, N; Rausch, CR; Ravandi, F; Shpall, E; Tidwell, RS; Wang, S; Ylimaz, M | 1 |
| Cao, S; Dong, Y; Tao, Q; Wang, J; Zhang, Q | 1 |
22 review(s) available for cytarabine and cladribine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New chemotherapeutic agents in acute myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotoxins; Leukemia, Myeloid; Oligonucleotides, Antisense; Retinoids; Vidarabine | 1996 |
Antimetabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Methotrexate | 1999 |
Nucleoside analogues in the treatment of haematological malignancies.
Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Cladribine; Clinical Trials as Topic; Cytarabine; Cytosine; Deoxycytidine; Dioxolanes; Economics, Pharmaceutical; Gemcitabine; Guidelines as Topic; Hematologic Neoplasms; Humans; Molecular Structure; Nucleosides; Pentostatin; Vidarabine | 2001 |
Successful treatment of refractory Langerhans cell histiocytosis with unrelated cord blood transplantation.
Topics: Bone Marrow; Cladribine; Combined Modality Therapy; Cyclosporine; Cytarabine; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Infant, Newborn; Mercaptopurine; Methotrexate; Methylprednisolone; Prednisone; Remission Induction; Transplantation, Homologous; Vinblastine | 2001 |
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Capecitabine; Cell Membrane; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Tumor Cells, Cultured; Vidarabine | 2002 |
Purine nucleoside analogues in the treatment of myleoid leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Pentostatin; Peripheral Blood Stem Cell Transplantation; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
[Treatment of systemic mastocytosis].
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Benzamides; Cladribine; Cytarabine; Diphosphonates; Enzyme Inhibitors; Histamine H1 Antagonists; Humans; Imatinib Mesylate; Interferon-alpha; Mastocytosis, Systemic; Photochemotherapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2003 |
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cladribine; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2004 |
[Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nucleoside Transport Proteins; Nucleosides; Phosphorylation; Vidarabine | 2005 |
Drug therapy for the treatment of Langerhans cell histiocytosis.
Topics: Anti-Inflammatory Agents; Antimetabolites; Brain Diseases; Cell Proliferation; Cladribine; Cytarabine; Drug Therapy, Combination; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Mercaptopurine; Practice Guidelines as Topic; Prednisone; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Thalidomide; Vinblastine | 2005 |
Juvenile xanthogranuloma with hematological dysfunction treated with 2CDA-AraC.
Topics: Cladribine; Cytarabine; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Infant; Male; Xanthogranuloma, Juvenile | 2010 |
ABC transporters and their role in nucleoside and nucleotide drug resistance.
Topics: Adenine Nucleotides; Arabinonucleosides; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cladribine; Clofarabine; Cytarabine; Drug Resistance; Humans; Neoplasm Proteins; Nucleosides; Nucleotides; Polymorphism, Single Nucleotide | 2012 |
Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine: case report and review of the literature.
Topics: Cladribine; Cytarabine; Dermatologic Agents; Drug Therapy, Combination; Humans; Infant; Male; Treatment Outcome; Xanthogranuloma, Juvenile | 2017 |
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Young Adult | 2017 |
Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Heart Diseases; Hematologic Diseases; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Liposomes; Meta-Analysis as Topic; Mucositis; Multicenter Studies as Topic; Neoplasms, Second Primary; Remission Induction; Survival Rate; Treatment Outcome | 2019 |
Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle-derived RNA.
Topics: Adult; Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Nucleophosmin; Remission Induction; Survival Rate | 2019 |
The role of cladribine in acute myeloid leukemia: an old drug up to new tricks.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Pharmaceutical Preparations; Remission Induction | 2020 |
Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cladribine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2020 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2023 |
30 trial(s) available for cytarabine and cladribine
| Article | Year |
|---|---|
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Topics: Adenosine Triphosphate; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Base Sequence; Biotransformation; Cladribine; Cytarabine; DNA Replication; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Data; Neoplasm Proteins; Neoplastic Stem Cells; Prodrugs; Ribonucleotide Reductases; Salvage Therapy | 1996 |
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence | 1996 |
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1997 |
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Bone Marrow; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction | 2002 |
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Survival Rate | 2003 |
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Rate | 2003 |
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2004 |
Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cladribine; Cytarabine; Female; Humans; Infant; Leukemia, Myeloid; Male; Recurrence; Treatment Outcome | 2004 |
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Po
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis | 2005 |
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Cladribine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Time Factors | 2008 |
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Remission Induction; Young Adult | 2009 |
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Candida; Cladribine; Cytarabine; Daunorubicin; Female; Fungemia; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Poland; Treatment Outcome; Young Adult | 2010 |
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine; Young Adult | 2012 |
Treatment outcome in older patients with childhood acute myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Transplantation, Autologous; Young Adult | 2012 |
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Staurosporine; Treatment Outcome; Tretinoin | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Prognosis; Survival Rate | 2015 |
Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.
Topics: Antineoplastic Agents; Child, Preschool; Cladribine; Cytarabine; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Infant; Langerhans Cells; Liver; Male; Recurrence; Spleen; Survival Analysis; Survival Rate; Vinblastine | 2015 |
Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Poland; Remission Induction | 2017 |
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Drug Resistance, Neoplasm; Edema; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome | 2017 |
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Poland; Prospective Studies; Remission Induction | 2020 |
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Filgrastim; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Mice, Inbred C57BL; Middle Aged; Remission Induction; Treatment Outcome; Triazoles; Young Adult | 2020 |
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Treatment Outcome | 2020 |
Cladribine-based debulking chemotherapy sequential with reduced intensity regimen and post-transplantation maintenance for refractory myeloid leukemia: a prospective phase II clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Cytoreduction Surgical Procedures; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Prospective Studies; Remission Induction; Transplantation Conditioning | 2022 |
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2022 |
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasm Recurrence, Local | 2023 |
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Sorafenib | 2023 |
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Sorafenib | 2023 |
92 other study(ies) available for cytarabine and cladribine
| Article | Year |
|---|---|
Role of organic cation transporters in the renal secretion of nucleosides.
Topics: Animals; Carrier Proteins; Humans; Ion Transport; Kidney; Membrane Proteins; Mice; Nucleosides; Oocytes; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Rats; Recombinant Proteins; Tetraethylammonium; Tubercidin; Xenopus laevis | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
Topics: Animals; Anti-Bacterial Agents; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Sequence Data; Nucleosides; Phosphotransferases (Alcohol Group Acceptor); Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cladribine; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; In Vitro Techniques; Leukemia; Lung Neoplasms; Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured; Urogenital Neoplasms | 1995 |
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Cladribine; Cytarabine; Daunorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluoresceins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1994 |
2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms.
Topics: Cladribine; Cytarabine; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Leukemia; Lymphoma, Non-Hodgkin; Mechlorethamine; Multiple Myeloma; Protein Binding; Tumor Cells, Cultured; Vincristine | 1993 |
[Effect of 2-chlorodeoxyadenosine, arabinoside cytosine and doxorubicin on acute myeloid leukemia clonogenic cell proliferation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cladribine; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1995 |
Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biotransformation; Breast Neoplasms; Carcinoma, Small Cell; Cladribine; Colonic Neoplasms; Cytarabine; Deoxycytidine Kinase; DNA, Complementary; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Genetic Vectors; Humans; Lung Neoplasms; Moloney murine leukemia virus; Phosphorylation; Recombinant Fusion Proteins; Tumor Cells, Cultured; Vidarabine | 1996 |
Seeking the nucleoside transporter.
Topics: Animals; Antimetabolites, Antineoplastic; Carrier Proteins; Cell Membrane; Cladribine; Cloning, Molecular; Cytarabine; Deoxycytidine; Erythrocytes; Gemcitabine; Glucose Transporter Type 1; Humans; Leukemia; Lymphoma; Membrane Proteins; Monosaccharide Transport Proteins; Nucleosides; Oocytes; Recombinant Proteins; Uridine; Vidarabine; Xenopus | 1997 |
Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs.
Topics: Adenosine; Amino Acid Sequence; Animals; Antineoplastic Agents; Carrier Proteins; Cladribine; Cloning, Molecular; Cytarabine; Databases, Factual; DNA, Complementary; Equilibrative Nucleoside Transporter 1; Humans; Membrane Proteins; Molecular Sequence Data; Nucleosides; Oocytes; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Tissue Distribution; Uridine; Vidarabine; Xenopus | 1997 |
Deoxycytidine in human plasma: potential for protecting leukemic cells during chemotherapy.
Topics: Adult; Cladribine; Cytarabine; Deoxycytidine; Deoxycytosine Nucleotides; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Human deoxycytidine kinase is located in the cell nucleus.
Topics: Amino Acid Sequence; Cell Compartmentation; Cell Nucleus; Cladribine; Cytarabine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Green Fluorescent Proteins; Humans; Luminescent Proteins; Molecular Sequence Data; Mutagenesis, Site-Directed; Nuclear Localization Signals; Nucleosides; Recombinant Fusion Proteins | 1997 |
Alterations in the properties of mouse leukemia L1210 cell lines selected by different methods for resistance to deoxyguanosine.
Topics: Animals; Cell Division; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Deoxyguanosine; Drug Resistance, Neoplasm; Kinetics; Leukemia L1210; Mice; Phosphotransferases (Alcohol Group Acceptor); Tumor Cells, Cultured | 1997 |
Activation of deoxycytidine kinase by various nucleoside analogues.
Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Arabinonucleosides; Cell Cycle; Cells, Cultured; Cladribine; Clofarabine; Cytarabine; Deoxycytidine Kinase; Enzyme Activation; HL-60 Cells; Humans; Leukemia; Lymphocytes; Palatine Tonsil; Thymidine Kinase; Tumor Cells, Cultured; Vidarabine | 1998 |
Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines.
Topics: Antineoplastic Agents; Arabinonucleosides; Cladribine; Cytarabine; Deoxyguanosine; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Luminescent Proteins; Microscopy, Fluorescence; Mitochondria; Nucleosides; Pancreatic Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Recombinant Fusion Proteins; Transfection; Tumor Cells, Cultured | 1998 |
Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Cladribine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Flow Cytometry; Fluorouracil; Humans; Jurkat Cells; Models, Theoretical; Necrosis; Radiotherapy; Tumor Cells, Cultured | 1998 |
Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Northern; Cladribine; Cytarabine; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; HL-60 Cells; Humans; RNA, Messenger | 1998 |
Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA.
Topics: Acute Disease; Antineoplastic Agents; Cladribine; Cytarabine; Fluorescence; Fluorometry; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Survival Analysis; Vidarabine | 1999 |
Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.
Topics: Antineoplastic Agents; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; K562 Cells; Leukemia, Erythroblastic, Acute; Phenotype; Vidarabine | 1999 |
Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study.
Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Autoradiography; Brain; Cladribine; Clofarabine; Cytarabine; Lipid Metabolism; Mice; Mice, Inbred C57BL; Thymus Gland; Tissue Distribution; Tritium; Vidarabine | 1999 |
Double minute chromosomes and c-MYC amplification in a child with secondary myelodysplastic syndrome after treatment for acute lymphoblastic leukemia.
Topics: Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Chromosome Aberrations; Chromosomes, Human, Pair 8; Cladribine; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Fatal Outcome; Female; Gene Amplification; Genes, myc; Humans; Hydrocortisone; Karyotyping; Mercaptopurine; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Vincristine | 2000 |
Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2000 |
Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antiviral Agents; Arabinonucleosides; Bromodeoxyuridine; Catalysis; Cell Division; Cell Nucleus; Cladribine; Cytarabine; Deoxycytidine; Drosophila melanogaster; Gemcitabine; Humans; Inhibitory Concentration 50; Kinetics; Osteosarcoma; Pancreatic Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Promoter Regions, Genetic; Retroviridae; Substrate Specificity; Thymidine; Thymidine Kinase; Transduction, Genetic; Tumor Cells, Cultured | 2000 |
Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide.
Topics: 5'-Nucleotidase; Blotting, Western; Cell Line; Cladribine; Cytarabine; Deoxycytidine Kinase; Deoxycytosine Nucleotides; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Etoposide; Fas Ligand Protein; Genes, MDR; Humans; Isoenzymes; Leukemia-Lymphoma, Adult T-Cell; Membrane Glycoproteins | 2001 |
Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience.
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Cladribine; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Prognosis; Treatment Outcome | 2001 |
Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carrier Proteins; Cell Survival; Child; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Immunophenotyping; Lymphocytes; Membrane Proteins; Nucleoside Transport Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 2002 |
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
Topics: Alkylating Agents; Antimetabolites; Benzamides; Bone and Bones; Busulfan; Cladribine; Combined Modality Therapy; Consciousness Disorders; Cytarabine; Drug Resistance, Multiple; Enzyme Inhibitors; Fatal Outcome; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunosuppressive Agents; Indomethacin; Infarction; Male; Middle Aged; Mitral Valve Stenosis; Pancytopenia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Splenectomy | 2002 |
Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
Topics: Acute Disease; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cladribine; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Neoplastic Stem Cells; Recurrence; Remission Induction; Tetrazolium Salts; Thiazoles; Translocation, Genetic; Trisomy | 2002 |
Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure.
Topics: Acute Kidney Injury; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Child; Cladribine; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Fatal Outcome; Hemofiltration; Humans; Leukapheresis; Leukemia, Monocytic, Acute; Male; Metabolic Clearance Rate; Recombinant Proteins; Remission Induction; Renal Dialysis; Urate Oxidase | 2002 |
Gastrointestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine.
Topics: Biopsy; Cladribine; Cytarabine; Drug Therapy, Combination; Gastrointestinal Diseases; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Infant; Male | 2003 |
Safety of rituximab therapy during the first trimester of pregnancy: a case history.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cladribine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant, Newborn; Lymphoma, Follicular; Male; Methotrexate; Mitoguazone; Peripheral Blood Stem Cell Transplantation; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Remission Induction; Rituximab; Safety; Transplantation, Autologous; Vincristine | 2004 |
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cladribine; Cyclophosphamide; Cytarabine; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Idarubicin; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Melphalan; Prednisolone; Survival Analysis; Vidarabine; Vincristine | 2004 |
Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Coloring Agents; Cytarabine; Deoxycytidine; DNA; Gemcitabine; HL-60 Cells; Humans; Inhibitory Concentration 50; Nucleosides; Tetrazolium Salts; Thiazoles; Vidarabine | 2004 |
In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
Topics: Adolescent; Adult; Antineoplastic Agents; Cell Death; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tumor Cells, Cultured; Vidarabine | 2005 |
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Hypereosinophilic Syndrome; Infusions, Intravenous; Middle Aged; Remission Induction | 2005 |
Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.
Topics: Antineoplastic Agents; Cell Line; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Lymphocytes | 2005 |
High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2005 |
Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Cytarabine; Drug Therapy, Combination; Female; Hematologic Diseases; Histiocytosis, Langerhans-Cell; Humans; Infant; Infusions, Intravenous; Male; Pilot Projects; Survival Analysis | 2005 |
Concomitant hairy cell and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Genetic Predisposition to Disease; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stem Cell Transplantation | 2006 |
Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Inhibitory Concentration 50; Oligonucleotide Array Sequence Analysis; Pemetrexed; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases | 2006 |
Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cytarabine; Directed Molecular Evolution; Drosophila melanogaster; Genes, Transgenic, Suicide; Genetic Therapy; Glioblastoma; Humans; Lethal Dose 50; Mutation; Neoplasms; Osteosarcoma; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Purines; Substrate Specificity; Transduction, Genetic; Vidarabine | 2007 |
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Odds Ratio; Poland; Recurrence; Salvage Therapy; Stem Cell Transplantation; Treatment Outcome | 2008 |
Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cladribine; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Radiography; Recurrence; Survival Rate | 2009 |
Salvaging AML with CLAG: novel option, or more of the same?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2012 |
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
Topics: Cell Line, Tumor; Cladribine; Cytarabine; Genetic Association Studies; HapMap Project; Humans; Leukemia, Myeloid, Acute; Linkage Disequilibrium; Pharmacogenetics; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2013 |
Langerhans cell sarcoma of the nasopharynx: a rare case.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cladribine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Humans; Langerhans Cell Sarcoma; Male; Nasopharyngeal Neoplasms; Prednisone | 2013 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult | 2014 |
Cladribine in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins | 2014 |
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cladribine; Clone Cells; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mass Spectrometry; Mice; Proteomics; Rituximab; Vidarabine; Xenograft Model Antitumor Assays | 2014 |
Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.
Topics: Antineoplastic Agents; Bone Marrow; Cladribine; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Genetic Therapy; Hematopoietic Stem Cell Transplantation; HL-60 Cells; Humans; Vidarabine | 2015 |
Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis.
Topics: Cladribine; Cytarabine; Drug Therapy, Combination; Female; Histiocytosis, Langerhans-Cell; Humans; Infant; Male; Retrospective Studies; Salvage Therapy | 2016 |
Risk organ + LCH gets the one-two punch?
Topics: Antineoplastic Agents; Cladribine; Cytarabine; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Male | 2015 |
Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Drug Synergism; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Karyotype; Leukemia, Myeloid, Acute; Treatment Outcome | 2016 |
The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
Topics: Adenine Nucleotides; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Child; Cladribine; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2016 |
[Effectiveness of CLAT Protocol for Treating Patients with Refractory Acute Myeloid Leukemia].
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thrombocytopenia; Topotecan; Young Adult | 2016 |
CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2016 |
[Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Young Adult | 2016 |
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Successful Treatment of Refractory Langerhans Cell Histiocytosis of the Choroid Plexus in a Child With Pulse Dexamethasone and Lenalidomide.
Topics: Choroid Plexus; Cladribine; Cytarabine; Dexamethasone; Diabetes Insipidus; Drug Resistance; Histiocytosis, Langerhans-Cell; Humans; Infant; Lenalidomide; Male; Pituitary Gland, Posterior; Prednisolone; Pulse Therapy, Drug; Remission Induction; Salvage Therapy; Skull Base; Thalidomide; Thoracic Vertebrae; Vinblastine | 2017 |
Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Exanthema; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Mucositis; Neutropenia; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diffusion Magnetic Resonance Imaging; Female; Histiocytic Sarcoma; Humans; Positron-Emission Tomography; Remission Induction; Salvage Therapy; Treatment Outcome | 2017 |
Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Propensity Score; Remission Induction; Retrospective Studies; Treatment Outcome | 2018 |
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Mutation; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
Eccrine squamous syringometaplasia in an allogenic stem cell transplant patient undergoing chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Drug Eruptions; Eccrine Glands; Epithelial Cells; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metaplasia; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Connecting the Dots: A Case of Myeloid Sarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cladribine; Cytarabine; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Sarcoma, Myeloid | 2018 |
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Cutaneous adverse events associated with purine analogs in the treatment of hairy cell leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Cohort Studies; Cytarabine; Drug Eruptions; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Pentostatin; Young Adult | 2019 |
Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cladribine; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Recurrence; Survival Rate; Treatment Outcome | 2019 |
Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Siblings; Transplantation, Haploidentical; Treatment Outcome | 2019 |
Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Remission Induction; Retreatment; Retrospective Studies | 2020 |
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cladribine; Cytarabine; Dendritic Cells; Doxorubicin; Hematologic Neoplasms; Humans; Male; Prognosis; Remission Induction; Salvage Therapy | 2020 |
Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report.
Topics: Adult; Busulfan; Cladribine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Melphalan; Mitoxantrone; Salvage Therapy; Transplantation Conditioning | 2020 |
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Consensus; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myeloproliferative Disorders; Neoplasm Grading; Predictive Value of Tests; Severity of Illness Index; Survival Rate; Young Adult | 2020 |
The global challenge of treating disseminated LCH.
Topics: Antineoplastic Agents; Child; Cladribine; Clofarabine; Cytarabine; Disease Management; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Incidence; Pediatrics; Protein Kinase Inhibitors | 2020 |
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2021 |
Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy.
Topics: Cladribine; Cytarabine; Humans; Karyotype; Leukemia, Myeloid, Acute; Mitoxantrone | 2021 |
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clofarabine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nucleophosmin; Treatment Outcome | 2021 |
[Recurrent and Refractory Langerhans Cell Histiocytosis in Children Treated with the Combination of Cladribine and Cytarabine].
Topics: Child; Cladribine; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Recurrence; Retrospective Studies | 2022 |
Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Retrospective Studies | 2022 |
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Topics: Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Prospective Studies; Retrospective Studies | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mitoxantrone; Respiratory Tract Infections; Sepsis | 2023 |
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
Topics: Child; Cladribine; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Neoplasm Recurrence, Local; Proto-Oncogene Proteins B-raf; Vemurafenib | 2023 |